Norelgestromin is a synthetic progestational hormone indicated in women to prevent pregnancy. This drug is also used in menopausal hormonal therapy. This drug is administered as a contraceptive pill or as a transdermal patch. This drug is also available in combination with ethinyl estradiol as a vaginal ring. Norelgestromin acts on the hypothalamic–pituitary–gonadal axis (HPG axis) where it binds to the progesterone receptor. This binding inhibits the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus. GnRH secretion is required to activate a luteinizing hormone (LH) surge that leads to ovulation. By its inhibition, the absence of LH results in no release of a viable egg from the ovaries. The thickening of the mucus interferes with sperm migration into the uterus for fertilization.
References
Norelgestromin Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Goa KL, Warner GT, Easthope SE: Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception. Treat Endocrinol. 2003;2(3):191-206. doi: 10.2165/00024677-200302030-00005.
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
